Experience of the use of trabectedin in pretreated unresectable, advanced, or metastatic soft tissue sarcoma in nine centers in Lebanon on a compassionate-use basis
| Autor: | E. A. Tueni, Marwan Ghosn, Georges Chahine, Walid Saad, Michel Saade, Francois G. Kamar, R. Farah, J. A. Makarem, M. Massoud, J. Kattan |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy biology business.industry medicine.medical_treatment Soft tissue sarcoma Compassionate Use Ecteinascidia turbinata medicine.disease biology.organism_classification Surgery Oncology Refractory medicine Curative surgery Sarcoma business Trabectedin medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 29:e20533-e20533 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.e20533 |
| Popis: | e20533 Background: Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors. Development of distant metastasis is frequent, even in patients undergoing initial curative surgery. Trabectedin, a tetrahydroisoquinoline alkaloid isolated from the Caribbean marine tunicate Ecteinascidia turbinata, was approved in 2007 by EMEA for patients with advanced STS after failure of previous lines chemotherapy. In this study, we retrospectively analyzed 15 patients who had been treated with trabectedin between 2008 and 2010 in 9 centers in Lebanon on a compassionate use basis. Methods: Fifteen patients with advanced refractory sarcoma were treated with trabectedin on a named patient compassionate basis program. All patients had been heavily pre-treated with at least 2 previous lines of chemotherapy. Results: The patients received a median of three cycles of treatment. Five patients achieved stable disease. The estimated 3 month progression-free survival median was 48%. Four patients experienced early... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|